20093 BAP Programme 2013 · 2013 Prizes and Awards 8 Acknowledgements 9 Programme in Detail Sunday 28th July 10 ... Guest Lecture: Helen Mayberg, Hall D on Monday at 11:45 Internet

arrogate

1 1

H 2013

CONTENTS BAPOfficersandCouncil 4

GeneralInformation 5LifetimeAchievementAward 72013PrizesandAwards 8Acknowledgements 9ProgrammeinDetail Sunday28thJuly 10 Monday29thJuly 12 Tuesday30thJuly 24 Wednesday31stJuly 36 BAPMembership 40

BAPOFFICE36CambridgePlace

HillsRoadCambridgeCB21NS

Tel:+44(0)1223358395Website:bap.org.uk

[email protected]

[email protected]

EducationCo-ordinatorandDigitalMediaDeveloperSarahChanning-Wright

[email protected]

Thescientificmaterialpresentedatthismeetingreflectstheopinionsofthecontributingauthorsandspeakers.TheBritishAssociationforPsychopharmacologyacceptsnoresponsibilityforthecontentsoftheverbaloranypublishedproceedingsofthismeeting.

Forreasonsbeyondourcontrolwehavetherighttoimmediatelyalterorcanceltheconferenceoranyarrangements,timetable,plansoritemsrelatingdirectlyorindirectlytotheconference.Theparticipantsshallnotbeentitledtoanycompensationfordamagesthatresultfromsuchalterationorcancellation.Itishighlyrecommendedthatallparticipantscarrytheproperindividualtravelandhealthinsurance.

TheBritishAssociationforPsychopharmacologyisregisteredinEnglandasaPrivateLimitedCompanyNo5866899.RegisteredCharityNo277825.RegisteredOffice:36CambridgePlace,HillsRoad,CambridgeCB21NS

2

BAP Summer Meeting 28-31 July 2013

2

Harrogate

arrogate

3 3

H 2013

HallH–Posters,Exhibition,Refreshments,Lunches

4


4

BAPOFFICERSANDCOUNCILMEMBERSUntilthe2013AnnualGeneralMeeting(29July,HallD)

OFFICERS President: BarbaraSahakian(Cambridge) President-elect: PaulHarrison(Oxford) Past-President: NicolFerrier(Newcastle)) HonoraryTreasurer: CatherineHarmer(Oxford) HonoraryGeneralSecretary: PeterHaddad(Manchester) MeetingsSecretary: JoNeill(Manchester) SecretaryforClinicalExternalAffairs: NaomiFineberg(WelwynGardenCity) SecretaryforNon-ClinicalExternalAffairs: PaulaMoran(Nottingham)

COUNCIL AnneJackson(Brighton) ValCurran(London) SteveBazire(Norwich) MarcusMunafo(Bristol) LizTunbridge(Oxford) MitulMehta(London) HughMarston(Edinburgh) PeterJones(Cambridge) OliverHowes(London)

Co-optedMembers:JeffreyNye(NewJersey)

MarkTricklebank(Windlesham)

Ex-OfficioCouncilMembers:BAPEditor:DavidNutt(London)

RCPsychSpecialCommitteeChair:AllanYoung(London)BAPDirectorofEducation:HamishMcAllister-Williams(Newcastle)

BAPPASTPRESIDENTS

HONORARYMEMBERS

GOVERNANCEPANEL

ProfessorGeorgeBeaumontDrAlecCoppenDrTimothyCornProfessorSusanIversenProfessorMalcolmLader

DrPaulLeberProfessorBrianLeonardProfessorEugenePaykelProfessorMertonSandlerProfessorHannahSteinberg

MaxHamiltonAlecCoppenPhilipBradleyMertonSandlerEugenePaykelSusanIversen

MalcolmLaderBrianLeonardStuartMontgomeryBarryEverittBillDeakinTrevorRobbins

DavidNuttCharlesMarsdenGuyGoodwinClareStanfordThomasBarnesGavinReynolds

ProfessorCharlesMarsden(Chair)DrClareStanfordProfessorGuyGoodwin

arrogate

5 5

H 2013

GENERALINFORMATIONAllactivitiestakeplaceatHarrogateInternationalCentre(HIC)unlessstatedotherwise

AbstractSupplement: ThenumbersnexttothepresentationsandpostersinthisProgramme aretheabstractnumbersasprintedintheSupplement

BAPAnnualGeneralMeeting: HallDonMondayat17:00

Blogging: SuziGage,anactiveandwell-knownscienceblogger,willbein attendanceatsomeofoursessions.SuziisaPhDstudentinscienceand herblogpostsappearontheGuardianwebsite.Suzihasalsobeen awardedoneofthefirstBAPPublicCommunicationPrizes,launched thisyear.TheBAPblogpostswillbehostedontheGuardiansiteand copiedontheBAPwebsite.

CertificatesofAttendance: WillbeemailedtoattendeesaftertheConference,uponrequest

CPD: ThismeetinghasbeenapprovedforContinuingProfessional DevelopmentbytheFacultyofPharmaceuticalMedicineandiseligible for24CPDpointsforfullattendance.

EditorialBoardMeeting(JoP): MeetingRoom1onTuesdayat12:45

EditorialBoardMeeting(TA): MeetingRoom1onTuesdayat13:45

Exhibition: HallHforthedurationoftheconference

GuestLecture: HelenMayberg,HallDonMondayat11:45

InternetCafé: FoyerofHallH

Luggagestorage: AcloakroomwillbeavailableatQueen’sSuiteforstoringluggageon Wednesdaymorning

Lunch: IncludedintheregistrationfeeinHallHandoutsideQueen’sSuiteon MondayandinHallHonTuesday

MentalHealthSession: Approachestonoveldrugdevelopmentfortreatmentofpsychiatric disorders–HallD,Mondayat15:00

NameBadges: MustbewornatalltimesatHIC.Ifyouloseyourbadgepleasecollect anotherfromtheBAPdesk.Werecyclenamebadgeholders–please leaveyoursattheBAPdeskbeforedeparture

PhotographyandRecording: ProhibitedduringoralsessionsexceptbytheofficialBAPphotographer. Pleaseseekpermissionfromthepresenterifyouwishtophotograph anyposterinHallH

Post-doctoralSymposium: Translationalautismresearchfordrugdiscovery Queen’sSuite1,Tuesdayat11:45

6


6

Posters: Session113:00-15:00onMonday-AffectiveDisorders1/Sleepand CircadianRhythms/LearningandCognition/Dementia/Anxiety/ EducationalPsychopharmacology/BrainImaging Session213:00-15:00onTuesday-AffectiveDisorders2/ Neuropharmacology/PsychomotorStimulants/SubstancesofAbuse/ Schizophrenia Postersmaybemountedfrom08:30onMondayand,wherever possible,shouldremaininplaceuntiltheendofthemeetingon Wednesday.Posterpresentersshouldstandbytheirposterforone hourduringtheirdesignatedsession

Prize-giving: 2013PrizesandAwardswillbepresentedattheConferenceDinner onTuesday

PsychopharmacologyAward OralpresentationsinQueen’sSuite1onTuesday16:00-17:00PrizeWinners:

Receptionand TheRoyalHall,Tuesdayat19:30ConferenceDinner: (forthosewhohavepurchasedaticket)

Refreshments: Includedintheregistrationfee AvailableoutsideQueen’sSuiteonSunday15:00-18:00andinHallH atdesignatedbreaksMondayonwards

RegistrationandInformation: BAPdeskoutsidetheQueen’sSuiteatthefollowingtimes: Sunday14:00-19:15 Monday08:30-17:30 Tuesday08:30-17:00 Wednesday09:00-12:30

SatelliteSymposia: Sunday–Sunovion,Queen’sSuite2at17:15 Monday–Lundbeck,Queen’sSuite1at13:00 Monday–Roche,Queen’sSuite2at13:00 Monday–Janssen,GardenRoomandRedLoungeattheOldSwan Hotelat18:00

ShortOralSessions: Tuesday15:00-16:00inHallDandQueen’sSuite1&2

SpeakerPreviewRoom: BetweenQueen’sSuiteandHallD

SpecialSession: SupportedbyServier,Queen’sSuite1onSundayat17:00

Symposia: 1,4,7inHallD;2,5,8inQueen’sSuite1;3,6,9inQueen’sSuite2

WelcomeReceptionandBuffet: Sunday19:30intheWedgwoodRestaurantandontheFrontLawnat theOldSwanHotel

Wi-Ficards: AvailableattheHICinformationdesk

Workshop: Sundayat14:00-17:00inKing’sSuite Workshopondevelopingguidingprinciplesongoodpracticewith respecttoanimalbehaviouralstudies

arrogate

7 7

H 2013

2013LIFETIMEACHIEVEMENTAWARD

The BAP Council is delighted to announce that the 2013 Lifetime Achievement Award will be presented to

ProfessorCharlesAMarsdenCharleswasborninCambridgeinMarch1943.HewenttoLondonUniversity,obtaininghisBScZoologyin1966.Althoughhe acquired aplace atDurhamUniversity to study ecology, he changed tack after reading an article describing the Falck-HillarpformaldehydefluorescencemethodtovisualisemonoaminecontainingpathwaysinthebrainandwenttoSouthamptonUniversityin1967tostudyforanMScinBiochemicalPharmacology.CharlesstayedonatSouthamptontodoaPhDonthecellularlocalisationofmonoaminesininvertebratebrainwhichheobtainedin1969.

HethenbecameAssistantLecturerattheUniversityofBergen,Norway(1969-1972)workingwithHansGuldberg,afterwhichhereturnedtotheUK,becomingaResearchFellow(MRC)attheInstituteofNeurology,LondonworkingwithGeraldCurzon.

In1977CharlesreadanarticlebyRalphAdamsinNatureonmeasuring5-HTreleasebyanewmethod,voltammetry,andreceivedfundingfromtheMRCtogoonasabbaticaltoAdams’labinKansasandlearnthetechnique.TheresultofthisresearchvisitwasthatCharlesbroughttheelectrochemicalsystemformeasuringmonoaminesbacktotheUK.

CharleswasappointedasaLectureratTheUniversityofNottinghamon1st January1978. HewasawardedaprestigiousWellcome Trust Senior Lectureship in August 1981 and became Reader inNeuropharmacology in 1983. He obtained hispersonal chair inNeuropharmacology inAugust1986and receivedaDSc fromSouthamptonUniversity in the sameyear.Charlesbecameco-directorofInstituteofNeuroscience,withPeterLiddlein2002andtogethertheysetupaninclusivevirtualresearch instituteandestablishedanewsletter toencourage research interaction,whichhasalwaysbeenhisstyle.CharlesalsohelpedasuccessfulbidtoestablishthefirstsmallanimalmagnetatNottingham.HehasalwayshadaproactiveinterestintrainingresearchersandtheinterdisciplinarydoctoraltrainingschemewasanothersuccessfuloutcomeoftheInstituteandreflectsCharles’ethos.InhistimeatNottinghamCharlessupervisedover70postgraduatestudentsandover30post-doctoralresearchfellowsworkedwithhim.ManyoftheseworkersarenowseniorscientistsintheUKandaroundtheworld.

ThebreadthofCharles’scientificinterestswithinpsychopharmacologyisimpressive,asishisabilitytomoveintonewareasofresearch.HewasamongthefirstpersonsintheUKtoundertakefluorescencehistochemistrytomapneuronalpathwaysinthebrain.Hecanclaimtobethefirstpersoninthiscountrytohaveusedinvivovoltammetry,helpingotherstosetupthismethod.Hewasapioneerintheuseofhighperformanceliquidchromatographycoupledwithelectrochemicaldetectionforthemeasurementofmonoaminesinthebrainandhecombinedthistechniquewithinvivomicrodialysistomeasuremonoaminereleaseintheconsciousanimal.Hehasalsobeenmuchinvolvedwithworkonbrainneuropeptidesandcannabinoids.Crucially,heissomeonewhohaslongrecognisedthatstudiesonbehaviour,particularlyanimalmodelsofpsychiatricdisorders,shouldbelinkedwithneurochemicalstudies,preferablyinthesameanimal.Manyofhisover300publishedpapersreflectthisapproach.

ThecommitmenttopsychopharmacologyasasubjectbyCharlesisdemonstratedbytheenergyhehasgiventonumeroussocieties.Hehashadalong-standingcommitmenttotheBritishAssociationforPsychopharmacology(BAP),beingonCouncilfor13years(1991-2004),MembershipSecretary(1995-96),andhasheldvirtuallyeveryotherofficerpostincludingProgrammeSecretary (1996-1998),PresidentElect (1998-2000),President (2000-2002),PastPresident (2002–2004)andChairof theGovernancePanel(2010-2013).CharleshasalsomadeamajorsustainedcontributiontotheSerotoninClubasacommitteememberandinhisroleasVice-President(1992–1994)andPresident(2002–2004).In2012hewasmadeanhonorarymemberof this scientific society,now renamed the International SerotoninResearchSociety.Both theSerotoninCluband theBAPflourishedunderhiswatchfuleyefordetailcombinedwithanabilitytoengageallthemembership.

CharleswasontheeditorialboardofTheBritishJournalofPharmacology(1980-1987),amemberofCommitteeoftheBritishPharmacologicalSociety(1995-1999)andasBPSRepresentativeonUKLSC(2001-present).HewasawardedJRVaneMedalbytheBritishPharmacologicalSocietyin2002forhisoutstandingcontributiontoneuropharmacologyandaFellowshipoftheBritishPharmacologicalSocietyin2006.CharleshasalsoservedontheeditorialboardofnumerousotherjournalsincludingNeuropharmacology,Psychopharmacology,SynapseandNeuroscience.

CharlesMarsdenhasplayedakeyroleinthedevelopmentandcontinuationofpsychopharmacologyintheUKforwellover40yearsandhaspioneeredapproachestothissciencewhichmanypeoplenowtakeforgranted.

WearedelightedthatCharleswillacceptthe2013LifetimeAchievementAwardattheconferencedinneronTuesday30July.

8


8

2013PRIZEWINNERS

BAPPSYCHOPHARMACOLOGYAWARDSTorewardthoseworkinginnon-clinicalandclinicalpsychopharmacologyOralpresentationswillbeonTuesday30Julyat16:00inQueen’sSuite1

The2013PsychopharmacologyAwardwinnersare:

AngelaAttwood(UniversityofBristol)Presentationtitle:D-cycloserinedoesnotimprovedrug-relatedcueexposure:

whatcanwelearnfromanimaldata?

JonathanRoiser(UniversityCollegeLondon)Presentationtitle:Individualdifferencesinpsychopharmacology:

Wheredotheycomefromandwhyshouldwecare?

Kuan-PinSu(ChinaMedicalUniversity)Presentationtitle:Omega-3fattyacidsindepression: Thebiological,therapeuticandpreventiveimplications

BAP/CAMBRIDGECOGNITIONAWARDTheBAPandCambridgeCognitionarestronglycommittedtopromotingandencouragingresearchintheareaofPsychopharmacologythatcoulddirectly,andinthenearterm,translatetopatientcare.TheBAP/CambridgeCognitionAwardexiststosupportthedevelopmentofnovelassessments,treatmentsalgorithms,interventions,orassistivetechnologies,andtoparticularlyrewardtranslationalapproaches

inPsychopharmacology.

The2013BAP/CambridgeCognitionAwardrecipientisMarcusMunafo,UniversityofBristol

Aposterdescribinghiswork,“Usingprototypicalfacesinstudiesofemotionrecognition“,willbedisplayedinHallH

HANNAHSTEINBERGBURSARYThankstothegenerosityofProfessorHannahSteinberg,afoundingmemberofBAP,andtheWolfsonFoundation,wearepleasedtoawardaspecialbursaryeachyearforattendanceattheSummerMeeting.TherecipientthisyearisAbigailBenn(UnivofBristol).AbigailwillpresentPosterMC19onMondayandwillpresentwithintheShortOralSession‘WindowsontheBrain’onTuesday

afternoon“Optogeneticstimulationofglutamatergicneuronesintherodentprefrontalcorteximprovesdiscriminationperformanceinanobjectrecognitiontask”

**NEW**BAPPUBLICCOMMUNICATIONPRIZESLaunchedthisyear,theBAPPublicCommunicationPrizeswillbeawardedannuallytorewardexcellenceinbothclinicalandnon-clinicalsciencecommunicationtothepublicintheareaof

psychopharmacology.Therearetwoprizes:oneforaTrainingMemberandoneforaFullMember.TheawardswillbepresentedattheConferenceDinneronTuesday.Thefirstwinnersare:

SuziGage(TrainingMemberPrize)andCarminePariante(FullMemberPrize)

LinkstoSuzi’sandCarmine’spublicinformationarticlesareavailableattheBAPwebsite.

POSTERPRIZESANDUNDERGRADUATEAWARDSDecisionswillbemadeduringtheconferenceandwinnersannouncedattheConferenceDinneron

Tuesday.

arrogate

9 9

H 2013

BURSARIESTheCouncilofBAPiscommittedtosupportingyoungscientistswithvariousinitiatives.Forthe

2013SummerMeetingwehaveawardedalmost60bursariestoassistTrainingMembers,Post-DocsandUndergraduatestoattendtheconference.

WeareextremelygratefultotheGatsbyCharitableFoundationfortheirgenerouscontributiontowardsthe2013bursaryfund.

POSTERPRESENTATIONS l AllpostersmustbeexhibitedinLANDSCAPEformat.

l Postersmaybemountedfrom08:30onMONDAY29JULY

l AllpostersmustbemountedwiththeVelcroprovided

l Conferencestaffwillremoveanypostercarryingadifferenttitletothatwhichis ontheacceptedabstract

l Presentersshouldstandbytheirposterforonehourduringtheirdesignatedsession

ORALPRESENTATIONSThetimeallocatedtoeachoralpresentationistoallowquestionsfrom,anddiscussionwith,theaudience.ThisinteractionisanimportantcomponentofBAPSummerMeetings,reflectingourphilosophyofpromotingdiscussionanddebate.Keepingtotimeisparticularlyimportantasattendeesoftenwishtoheartalksindifferentsessions.Sessionchairsareaskedtostrictlyenforcethetimeallocatedtoeach

presenter.

ACKNOWLEDGEMENTSBAPacknowledgescontributionsfromthefollowing,whowilltakepartinthe2013summer

meetingbysupportingaSpecialSession,Satellitesandexhibitionstands

JanssenLundbeckRocheServierSunovion

CampdenInstrumentsShireTracksys

10


10

FULLPROGRAMMEPLEASENOTE:AllactivitiestakeplaceatHarrogateInternationalCentre(HIC)unlessstatedotherwise

SUNDAY28JULY14:00 RegistrationandInformationdeskopensoutsideQueen’sSuite

14:00-17:00 Workshopondevelopingguidingprinciplesongoodpracticewithrespecttoanimal behaviouralstudies King’sSuite,HIC A joint initiative by the Laboratory Animals Association (LASA) the BAP, BNA and ESSWAP to develop guidance based on current expert opinion that offers advice on what researchers need to think about before embarking on animal behavioural studies

16:00 TeaandcakesoutsideQueen’sSuiteforthoseattendingtheBAPSpecialSessionor theSatelliteSymposiumat17:00

17:00-19:00 BAP Special Session supported by Servier Queen’sSuite1,HIC

Getting better at treating mood disorders: lessons from mechanistic and clinical studies ChairedbyOliverHowes(InstofPsychiatry)

17:00 WelcomeandIntroduction OliverHowes(InstofPsychiatry)

17:10 Whatunderliesantidepressantresponseandwhatthismeansfortreatment CatherineHarmer(UnivofOxford)

17:50 Gettingthembetterandkeepingthemwell GuyGoodwin(UnivofOxford)

18:30 Discussion

19:00 Endofsession

Sunday

arrogate

11 11

H 2013

Sunday

17:15-19:00 Satellite symposium hosted by Sunovion Queen’sSuite2,HIC

Key challenges in antipsychotics’ tolerability ChairedbyThomasBarnes(ImperialCollegeLondon)

17:20 Mechanismsofantipsychotic-inducedmetabolicsideeffects GavinReynolds(SheffieldHallamUniv)

17:45 Q&A

17:50 Monitoringthemetabolicsideeffectsofantipsychotics:aPOMH-UKquality improvementprogramme ThomasBarnes(ImperialCollegeLondon)

18:15 Q&A

18:20 Antipsychoticinducedhyperprolactinaemia:Problemsandsolutions PeterHaddad(UnivofManchester)

18:45 Q&AandClosingRemarks

19:30 Welcome Reception at The Old Swan Hotel IntheWedgwoodRestaurantandoutsideontheFrontLawn Delegatesareinvitedtoattendfordrinksandabuffetmeal EntertainmentfromtheChrisWhiteJazzTrioandStuartFletcherDisco TheBAPPresident,BarbaraSahakian,willgiveashortwelcomeaddressat20:00

12


12 Monday

MONDAY29JULY08:30 BAPdeskopensintheFoyeroftheQueen’sSuite

09:00 Symposia1,2and3inparallel HallD,Queen’sSuite1,Queen’sSuite2

SYMPOSIUM 1 – Hall D Theneurobiologyofsocialbehaviour:pharmacologicalmanipulationandrecent advancesintherapy ChairsJoNeill(UnivofManchester)andJørgenScheel-Krüger(AarhusUniv)

09:00 AntoniaHamilton(UnivofNottingham) S01 Socialbehaviourandtop-downcontrolinautism

09:30 JørgenScheel-Krüger(AarhusUniv) S02 Prenatalvalproateasarodentmodelforautism

10:00 RefreshmentsinHallH

10:30 LoukVanderschuren(UtrechtUniv) S03 Theneurobiologyofsocialplaybehaviorinrats

11:00 EricPrinssen(F.Hoffman-LaRoche,Basel) S04 Discoveringnoveltherapiesfornegativesymptomsofschizophreniaby usingrodentmodelsofsocialwithdrawal

SYMPOSIUM 2 – Queen’s Suite 1 Brain-derivedneurotrophicfactor(BDNF)andsynapticplasticityasadrugtargetfor cognitivedysfunctioninCNSdisorders Chairs:PradeepNathan(UnivofCambridge),LilanaMinichiello(UnivofOxford)

09:00 LilianaMinichiello(UnivofOxford) S05 BDNF-TrkBsignalinginstriatalenkephalinergicneuronscontrolsinhibition oflocomotorbehaviour

09:30 CharlotteOomen(Germany) S06 BDNFinteractswithimmatureneuronsinthehippocampusduringmemory andpatternseparation


10:30 PradeepNathan(Cambridge) S07 EffectoftheBDNFVal66Metpolymorphismonsynapticandcognitive functioninhealthysubjects

arrogate

13 13

H 2013

Monday

11:30 PaulMaruff(CogStateLtd,Melbourne) S08 ModulationofAβamyloid-relatedcognitivedeclinebybrain-derived neurotrophicfactorVal66MetpolymorphisminpreclinicalAlzheimer’s disease

SYMPOSIUM 3 – Queen’s Suite 2 ExperimentalMedicineapproachesindevelopingnewtreatmentsforanxiety disorders Chairs:DavidBaldwin(UnivofSouthampton)andDavidNutt(ImperialCollege, London)

09:00 NicvanderWee(LeidsUnivMedischCentrum) S09 Whereistheroomforimprovementinthedrugtreatmentofanxiety disorders?

09:30 GerryDawson(P1vitalLtd,Oxford) S10 Whathasexperimentalmedicineeverdoneforus?


10:30 SallyAdams(UnivofBristol) S11 Whatdostudiesofcognitivebiasmodificationreveal?

11:00 MattGarner(UnivofSouthampton) S12 Howgoodisthe7.5%CO2inhalationmodelofGeneralizedAnxiety Disorder?

11:45 BAP ANNUAL GUEST LECTURE – Hall D Chaired by Barbara Sahakian

RethinkingDepressionanditsTreatment: InsightsfromStudiesofDeepBrainStimulation Helen S Mayberg ProfessorofPsychiatry,NeurologyandRadiologyandtheDorothyFuquaChairin PsychiatricImagingandTherapeuticsatEmoryUniversitySchoolofMedicine

Criticaltothedevelopmentofdeepbrainstimulation(DBS)asanovel therapyforpatientswithtreatmentresistantdepressionhasbeen thecharacterizationofbrainsystemsmediatingnormalandabnormal moodstatesaswellasthosemediatingsuccessfulandunsuccessful responsetovariousantidepressantinterventionsusingfunctional neuroimagingThetheoreticalanddata-drivenfoundationforthisnew treatmentstrategyaswellasresultsfromongoingexperimentalstudies willbepresented.

14


14 Monday

13:00-14:00 Satellite Symposium hosted by Lundbeck – Queen’s Suite 1

OpioidModulatorsinAlcoholDependence:Growingpotentialfortreatmentina non-specialistsetting ChairedbyAnneLingford-Hughes(ImperialCollege,London)

Opioidreceptorsandtheirandrelevancetoalcoholdependence DavidNutt(ImperialCollege,London)

Emergingclinicaldataonnewtreatmentmodalitiesforalcoholdependence JonathanChick(SpireHospital,Edinburgh)

13:00-14:00 Satellite Symposium hosted by Roche Products Ltd – Queen’s Suite 2

SheddingLightonNegativeSymptomsofSchizophrenia ChairedbyBillDeakin(UnivofManchester)

Whenthedrugsdon’twork:imagingdataontheneurobiologyofrefractory symptomsinschizophrenia OliverHowes(InstofPsychiatry,London)

Thetroublewithnegativesymptoms DavidTaylor(MaudsleyHospital,London)

13:00-15:00 PosterSession1–HallH

AffectiveDisorders1/SleepandCircadianRhythms/LearningandCognition/ Dementia/Anxiety/EducationalPsychopharmacology/BrainImaging

MONDAY GROUP A: AFFECTIVE DISORDERS 1

Antidepressants,polyunsaturatedfattyacidsandglucocorticoidpre-treatmentmodulate MA01 inflammatoryresponsesinhumanhippocampalprogenitorcellsHorowitz MA,AnackerC,WertzJ,ParianteC,ZunszainP

Investigatingtheeffectofpre-treatmentsleepabnormalitiesontheemergenceof MA02 interferon-α-induceddepressivedisorderinacohortofHIVandhepatitisCviruscoinfected patientsBerry A,FialhoR,FileA,KellerM,TibbleJ,HaqI,WhaleR

Depressionandhealth-relatedqualityoflifeinpatientswithhepatitisCundertaking MA03interferon-alpha(IFN-A)treatmentBorsini AB,HepgulN,MondelliV,ParianteCM

Interferon-alpha-induceddepression:theinvolvementofthekynurenineandtryptophanpathway MA04Hepgul N,BorsiniA,MondelliV,HotopfM,ZunzsainP,MyintAM,ParianteCM

arrogate

15 15

H 2013

Monday

Omega-3fattyacidsinthepreventionofinterferon-alpha-induceddepression MA05Su KP Lai HC,YangHT,SuWP,PengCY,ChangJPC,HuangCL,ParianteCM

INFLAME-BEAT:Elevatedinflammationandneurotoxicdiversioninthekynureninepathwayof MA06 tryptophanmetabolisminheartdiseasepatientswithdepressionNikkheslat N,ZunszainPA,BarbosaIG,ParkerJA,TyleeAT,CarvalhoLA,ParianteCM

Asystematicreviewofinflammatorybiomarkersinrelationtotreatment-resistantaffective MA07 disorderStrawbridge R,CleareA,PapadopoulosA

GeneexpressionaspredictorsofantidepressantresponseusingROCAnalysisintheGENDEP MA08 studyCattaneo A,GennarelliM,UherR,BreenG,FarmerA,AitchisonKJ,CraigIW,AnackerC, ZunszainPA,McGuffinP,ParianteCM

Developingananimalmodeltostudyinflammationandstressindepression MA09Musaelyan K,ZunszainPA,MeertTF,ParianteCM,ThuretS,FernandesC

Exposuretoantenataldepression,neonatalbehaviouraldysregulationandthe MA10 hypothalamic-pituitary-adrenal(HPA)axisPreviti G,ConroyS,FantiniE,DuPreezA,OsborneS,ZunszainP,PawlbyS,AgugliaE, ParianteC

Theeffectofchronicrestraintstressonanxiety-relatedbehaviourintheelevatedplusmazein MA11 juvenilemiceSadler AM,BaileySJ

Effectsofintrauterinestressonadulthoodage-relateddisease:a25yearprospectiveinvestigation MA12Plant DT,PawlbyS,ParianteCM

Hypothalamic-Pituitary-Adrenal(HPA)axisresponsetosocialstressorsindepression,PTSDand MA13 psychosisCiufolini S,MondelliV,KemptonM,ParianteC,DazzanP

Usinggrowthmixturemodellingtoanalysediurnalcortisoldata:apilotstudy MA14Wertz J,NikkheslatN,MondelliV,ConroyS,OsborneS,VecchioC,PaulsA,DazzanP, ParianteC,ZunszainP

Haircortisolanalysisinpsychiatricillnesses-areview MA15Herane A,PapadopoulosA,DeAngelV,RiscoL,CleareA

Theantiglucocorticoidaugmentationofanti-depressantsindepression(ADD)study: MA16 methods,recruitmentandpatientcharacteristicsRyles F,LandaS,McAllister-WilliamsRH,WatsonS,AndersonIM,ApekeyT,BarkerS, BulmerS,FarrowC,FinkelmeyerA,GillN,GrunzeHCR,HaddadPM,HileyJ,HughesTA, LloydA,McCollEMM,SiddiqiN,SinhaB,SmithE,SteenN,StevensL,SturrockA,SymondsC, YatesS,WainrightJ,WatkinsonH,WilliamsK,FerrierN

16


16 Monday

Aldosteroneincreasesearlierthancorticosteroneinnewanimalmodelsofdepression: MA17 Isthisanearlymarkerfordepressiononset?Franklin M,JezovaD,HlavacovaN,SingewaldN,MurckH

Aldosteroneandbloodpressureinyoungpeopleatincreasedriskofdepression MA18Williams C,MannieZN,DieschJ,FranklinM,LeesonP,CowenPJ

Anovelanimalmodelforautism MA19Bertelsen F,MøllerA,LandauAM,Scheel-KrügerJ

Childhoodtraumainbipolardisorder MA20Dougall D,WatsonS,GallagherP,PorterRJ,BasuS,PalanichamyN,MoncrieffJ,FerrierIN, YoungAH

Quetiapine’seffectsonemotionalprocessingandsleepopposeabnormalitiesseeninbipolar MA21 phenotypeRock PL,HarmerCJ,FosterR,WulffK,GoodwinGM

Alongitudinalexaminationoftheeffectoflithiummaintenancetherapyonglomerularfunction MA22 inpatientswithaffectivedisorders:apopulationbasedcohortstudy(2000-2011)Clos S,RauchhausP,SevernA,DonnanP

Comparativeanalysisoftreatmentsforthepreventionofmanicanddepressiverelapsein MA23 bipolardisorderTaylor MJ,GoodwinE

MelatoninInacutemaniainvestigation(MIAMI-UK)-preliminaryresultsfromanRCT MA24Economou A,SharpleyAL,GibsonJ,CordeyJ,deCrescenzoF,LawsonJ,VoyseyM,RylandsA, AlTaierH,LennoxA,DebT,LoomesR,KayR,MatthewsN,RendellJ,AhmadF,GeddesJR, QuestedDJ

MONDAY GROUP B: SLEEP AND CIRCADIAN RHYTHMS Theeffectsofcaffeineandglucosedrinksonasimulatedmorningdrivetoworkafterrestricted MB01 sleepAlford CA,DugganB Insomniaandrisktaking MB02Baker LD,KennyL,WingfieldM,LymnJ,WickensR,SavageJ,FairchildG,BaldwinDS, GarnerM Sleepdisturbanceandpainseverity:Theinfluenceofaffectiveandattentionalstate MB03Harrison L,WilsonS,MunafoMR Managementofinsomniawithingeneralpractice:aquestionnaireandqualitativeinterviewstudy MB04EverittH,LeydonG,LittleP,Baldwin DS

arrogate

17 17

H 2013

Monday

MONDAY GROUP C: LEARNING AND COGNITION

Effectsoflevocetirizine(5mg)andhydroxyzine(50mg)oncognitiveandpsychomotor MC01 performanceduringsimulateddivingat30and10metersKienhorstEAM,vanOoijPJAM,vanHulstRA,Verster JC

ProfilingcognitivedysfunctionacrosstherapeuticareasusingtheCambridge MC02 NeuropsychologicalTestAutomatedBattery(CANTAB)Hermans LF,RockPL,HousdenCR,RiedelW

D-cycloserinedoesnotimprovedrug-relatedcueexposure:whatcanwelearnfromanimaldata? MC03Attwood AS,HogarthL,AdamsS,HowellE,MunafoMAngela Attwood has won a 2013 BAP Psychopharmacology Award. She will present her work orally at 16:00 on Tuesday

Effectsofrewardexpectancyonattentionalbiasforrewardingstimuliareoutcome-specific MC04Jedras P,JonesA,FieldMThis will also be presented orally at 15:30 on Tuesday

Theeffectofarousalonattentionalbiastorewardingcues MC05Jones A,Barrett-PinkC,FieldM

NeurocognitiveendophenotypesinadultAttentionDeficit/HyperactivityDisorder(ADHD) MC06Pironti VA,MullerU,LaiMC,SucklingJ,BullmoreE,SahakianBJ

RecognitionofHappinessandSadnessinDepressedPatients:Ameta-analyticreview MC07Dalili MN,Penton-VoakIS,MunafoMR

HabenularesponsesduringappetitiveandaversiveconditioninginMajorDepressiveDisorder MC08Lawson RP,NordCL,SeymourB,DolanRJ,DayanP,WeiskopfNW,RoiserJP

Faceemotionrecognitionindepression:clarifyingtheroleofchildhoodtrauma MC09Suzuki A,PoonL,KumariV,CleareA

Decisionmakingandrisktakinginyoungpeopleatincreasedriskofdepression MC10Mannie Z,WilliamsC,BrowningM,CowenP

Evidenceforspecifictaskswitchingdeficitsinveganism MC11Kehagia A

MethylphenidatemodulatesworkingmemorynetworksandbehaviouralperformanceinTBI MC12 patientsManktelow AE,MenonDK,SahakianBJ,VermaV,StamatakisEA

TheeffectofKetamineonfunctionalconnectivityanditsmodulationbyRisperidoneand MC13 LamotrigineJoules R,DoyleOM,O’DalyO,DeSimoniS,MehtaMAThis will also be presented orally at 15:30 on Tuesday

18


18 Monday

TheeffectofMDMAadministrationonthepruningofdecisiontrees MC14Faulkner P,HuysQ,CurranHV,NuttD,Carhart-HarrisR,ErritzoeD,DayanP,RoiserJThis will also be presented orally at 15:45 on Tuesday

Aproof-of-conceptinvestigationofgenotype-dependentnoradrenergiceffectsonimpulsivity MC15Knight JA,WadeMA,GibbsAA

EffectsofBDNFandKIBRAsinglenucleotidepolymorphismsonhumanmemoryrelatedbrain MC16 activationSchwab LC,NathanPJ,HensonRN,SucklingJ,MiskowiakKW,OoiC,TaitR,SolteszF, LawrenceP,MaltbyK,SkeggsA,MillerSR,McHughS,GuanX,LuB,BullmoreE,DoddsCM

Cognitiveprofilesofselective5-HT1Aagonistsinrodentmodelsofsustainedattention, MC17 impulsivityandworkingmemoryFodder AF,Newman-TancrediA,VarneyM,ShoaibM

Thebehaviouralresponsetothealpha2Aadrenoceptoragonist,guanfacine,differsin MC18 neurokinin-1receptorknockout(NK1R-/-)andwildtypemicePillidge K,GrimméAJ,TsaiYC,HealDJ,StanfordSC

Optogeneticstimulationofglutamatergicneuronesintherodentprefrontalcorteximproves MC19 discriminationperformanceinanobjectrecognitiontaskBenn A,StuartSA,BarkerGRI,TeschemacherA,WarburtonEC,RobinsonESJThis will also be presented orally at 15:00 on TuesdayAbigail Benn has been awarded the 2013 Hannah Steinberg BAP Conference Bursary

TheKIBRApolymorphismisassociatedwithabnormalsynapticactivityandbehavioural MC20 performanceduringerrorprocessingClarke CL,NathanPJ,LawrenceP,BentleyG,DoddsC,MillerSR,WilleD,McHughS, ByrneM,BelgroveM,BullmoreE,SolteszF

TheeffectofBDNFval66metpolymorphism“metload”onerrorprocessing MC21Soltesz F,LawrenceP,ByrneM,BelgroveM,CroftR,BentleyG,DoddsC,SucklingJ,LuB, BullmoreE,NathanP

MONDAY GROUP D: DEMENTIA

BehaviouralandcognitivedeficitsinthehTaumurinemodeloftauopathies MD01Geiszler PC,KnappS,ChambraudB,BaulieuEE,PardonMC

Synapticandcognitivedeficitsinducedbyintracerebroventricularinjectionofsolubleamyloid-b MD02 oligomersinratsHarte MK,McLeanS,MarshS,GraysonB,FicherN,LefebvreT,KozielV,NeillJC,PillotT

Optimising[18F]-fallyprideimagingforD2/3receptoroccupancystudiesinAlzheimer’sDisease MD03Clark-Papasavas C,DunnJT,GreavesS,MoggA,BrowningsS,NwosuB,LuiK,MarsdenP, JoemonJ,CleijM,KapurS,KesslerR,HowardR,ReevesSJ

arrogate

19 19

H 2013

Monday

Souvenaid®,auniquenutrientcombinationhasbeenshowninclinicaltrialstoimprovememory MD04 inearlyAlzheimer’sDiseaseSmith N

Auditofanti-dementiadrugprescribinginaninpatientsetting MD05Nazir E,IlieL,ReesEFY

Prescribingofantipsychoticsinpatientswithdementiaininpatientsetting–isourpractice MD06 mirroringtheNICEGuidelines?Nazir E,IlieL,SammyM

Serviceevaluation:ImpactofroutinespecialistassessmentsinanElderlyMentallyInfirm(EMI) MD07 nursinghomeNazir E,ReesE,DaviesJ

MONDAY GROUP E: ANXIETY

Impactofremissionofobsessive-compulsivedisorderandsyndromeonprognosticationand ME01 treatmentstrategiesBergbaum CE,FinebergNA,HengartnerMP,GaleT,RösslerW,AngstJ

Developinganewscheduleforassessingtheonsetofsymptomsandlatencytotreatmentin ME02 psychiatricdisorders:aninternationalcomparisonPalazzo MC,Dell’OssoB,CamuriG,AltamuraAC,BaldwinDS

Adoseofruthlessness:interpersonalmoraljudgmentishardenedbytheanti-anxietydrug ME03 LorazepamPerkins AM,EttingerU,LeonardA,KruegerK,DaltonJ,MehtaMA,KumariV,WilliamsSCR

Differentialimpactofanxietysymptomsandanxietydisordersontreatmentoutcomefor ME04 psychoticdepressionintheSTOP-PDstudyDavies SJC,MulsantBH,FlintAJ,RothschildAJ,WhyteEM,MeyersBS

Effectof7.5%CO2inhalationonthehumaneye-blinkstartleresponse ME05Pinkney VL,WickensR,MilerJ,BamfordS,BaldwinDS,GarnerM

AninvestigationofneuroimmunologicalandcognitivefactorsinGeneralisedAnxietyDisorder ME06 -anassociation?Southgate BD,TangZ,RochesterJJ,BrowningT,FairfieldS,LovelessT,AliB,CullifordD, GarnerM,BaldwinD,HouR

Prebioticintakereducesthewakingcortisolresponseandaltersemotionalbiasinhealthy ME07 volunteersSchmidt K,CowenP,HarmerCJ,TzortzisG,BurnetPWJ

20


20 Monday

Theeffectofprefrontaltranscranialdirectcurrentstimulationonattentionnetworkfunction ME08 inhealthyhumansMiler JA,MeronD,BaldwinDS,GarnerMThis will also be presented orally at 15:45 on Tuesday

Comparableeffectsof7.5%carbondioxideinhalationandtraitanxietyonattentioncontrol ME09Garner M,AinsworthB,MunafoMR,BaldwinDS

MONDAY GROUP F: EDUCATIONAL PSYCHOPHARMACOLOGY

AuditofPhysicalHealthMonitoringinOldagePsychiatricinpatientunitWellerWingBedford MF01 HospitalAftab A,ShahS,HaqR,SuleA

SSRItakingandemotional/clinicalrespondinginBorderlinePersonalityDisorder MF02Zirk-SadowskiJ,SinghR,YathirajK,HarwoodS,SzalmaB,OwensB,ColquhounA, DenmanC,Dudas R

Natureandprevalenceofpsychotropicdrugprescribingforpeoplewithpersonalitydisorder MF03Paton C,BhattiSF,CrawfordMJ,BarnesTRE

DAREToMakeaDifferenceProjectEvaluation(2011-2012)forPrimaryandSecondarySchools MF04Nazir E

TranslationalDrugDiscoveryattheUniversityofSussex MF05Atack J

MONDAY GROUP G: BRAIN IMAGING

Psychosis-likeeffectsofketamine-relationshiptobrainactivity MG01Stone J,DietrichC,ReedL,DeSimoniS,MehtaM,KrystalJ,BarkerGJThis will also be presented orally at 15:45 on Tuesday

TheeffectofMDMAonrecollectingemotionallypotentautobiographicalmemories:anfMRI MG02 studywithimplicationsforMDMA-assistedpsychotherapyCarhart-Harris RL,WallMB,ErritzoeD,KaelenM,FergusonB,DeMeerI,TannerM, BloomfieldM,WilliamsTM,BolstridgeM,StewartL,MorganC,NewbouldRD,FeildingA, CurranHV,NuttDJ

Theanarchicbrain:usingdynamiccausalmodellingtoassesstheeffectofpsilocybinoneffective MG03connectivitywithinthedefaultmodenetworkKaelen M,KahanJ,MoranJ,HamT,WallM,FeildingA,NuttD,Carhart-HarrisRL

arrogate

21 21

H 2013

Monday

TheeffectsofpsilocybinandMDMAonhippocampalrestingstatefunctionalconnectivity MG04Williams LTJ,Carhart-HarrisRL,ErritzoeDE,WilliamsTM,StoneJM,ReedL,TyackeRJ, LeechR,HobdenP,EvansJ,FeildingA,WiseRG,NuttDJ

Behaviouralandneuralresponsestocollectivedecision-makinginhumans MG05Charpentier CJ,MoutsianaC,GarrettN,SharotT

Effectsofsatiationonbrainresponsestorewardingandaversivestimuli MG06Thomas JM,HiggsS,DourishCT,HansenP,HarmerCJ,McCabeC

ChangesinsynapticGABAconcentrationsarenotmeasurableusingMRspectroscopy MG07Myers JFM,EvansCJ,KalkNJ,EddenRAE,Lingford-HughesAR

Effectofnaltrexoneonneuralrewardandaversiveprocessing;implicationsforcompulsive MG08 disordersMcCabe C,MurrayE,BrouwerS,McCutcheonR,HarmerCJ,CowenPJ

InvestigationofTSPOstatusinthehumanbraininalcoholdependence:a[11C]PBR28PETstudy MG09Kalk NJ,GuoQ,OwenD,WaldmanA,DarK,GunnRN,NuttDJ,RabinerEA, Lingford-HughesAR

Imagingtheimidazoline2bindingsitewiththenovelPETligand[11C]BU99008inahigher MG10 species:EvaluationandcharacterisationTyacke RJ,ParkerCA,NabulsiN,HoldenD,LinS-F,LabareeD,KealeyS,GeeAD,HusbandsSM, CarsonRE,HuangY,NuttDJ

Assessmentofendogenousopioidpeptidereleasewithradioligandbinding–InVitroandEx MG11 VivoStudieswith[3H]Diprenorphineand[11C]CarfentanilQuelch DR,ParkerCA,KatsouriL,LanzaroneS,NuttDJ,TyackeRJ

Mappingstressresponsesusingmanganese-enhancedmagneticresonanceimaging(MEMRI) MG12Thakrar C

15:00 BAP Plenary Mental Health Session – Hall D Approachestonoveldrugdevelopmentfortreatmentofpsychiatricdisorders Chairs:JeffreySNye(JanssenPharmaceuticals)andBarbaraJSahakian(Univof Cambridge)

15:00 Introduction JeffreyNye(JanssenPharmaceuticals)

15:10 Developmentofrapidlyactingantidepressantdrugs WayneDrevets(LaureateInstforBrainResearch)

15:30 Glutamatergicapproachesforpsychiatricdisorders JosephWettstein(F.Hoffmann-LaRocheLtd)

22


22 Monday

15:50 Discussant TrevorRobbins(UnivofCambridge)

16:10 QuestionsandDiscussionwiththeaudience BarbaraSahakian(UnivofCambridge) 16:45 Endofsession

17:00 British Association for Psychopharmacology Annual General Meeting – Hall D BAPMembersonly ChairedbyProfessorJoNeill,MeetingsSecretary

1.PresidentialAddress ProfessorBarbaraSahakian 2.Motionsforapproval:

2.1ThattheMinutesofthe2012AnnualGeneralMeetingbeadoptedasa correctrecord ProfessorBarbaraSahakian

2.2ThattheEditor’sReportbereceived ProfessorDavidNutt

2.3ThattheTrustees/DirectorsAnnualReportandauditedaccountsfor theperiod1Januaryto31December2012bereceivedandadopted ProfessorCatherineHarmer

2.3.aProposalthattheFullMembershipsubscriptionbeincreasedto£100 fromMarch2014 ProfessorCatherineHarmer

2.4

arrogate

23 23

H 2013

Monday

ThattheHonoraryGeneralSecretary’sReportbereceived DrPeterHaddad

2.5ThattheGovernancePanel’sReportbereceived ProfessorCharlesMarsden

3.Discussion

18:45-21:00 Satellite Symposium hosted by Janssen – Garden Room and Red Lounge, The Old Swan Hotel Drugdevelopment:Theorytopractice ChairedbyPeterHaddad(UnivofManchester)

18.00-18.45 Arrivalandbuffet

18.45-19.00 Introduction&Welcome PeterHaddad(UnivofManchester)

19.00 Canweimprovenomenclatureinpsychopharmacology? DavidNutt(ImperialCollege,London)

19:30 Drugdevelopment:EfficacyvEffectiveness LudgarHargartar(Janssen)

20.00 Theplaceofobservationalstudiesinassessingtheeffectivenessoflongacting injectableantipsychotics PeterHaddad(UnivofManchester)

20.30 Q&A

24


24 Tuesday

TUESDAY30JULY08:30 BAPdeskopensintheFoyeroftheQueen’sSuite

09:00 Symposia 4, 5 and 6 in parallel HallD,Queen’sSuite1,Queen’sSuite2

SYMPOSIUM 4 – Hall D Imagingdopamineinthelivingbrain Chairs:ElizabethTunbridge(UnivofOxford)andPaulHarrison(UnivofOxford)

09:00 MarkUngless(ImperialCollege,London) S13 Listeningtodopamineneuronsusinginvivoelectrophysiology

09:30 MarkWalton(UnivofOxford) S14 Usingfast-scancyclicvoltammetrytovisualisereal-timedopaminereleasein behavinganimals


10:30 ElizabethTunbridge(UnivofOxford) S15 Theimpactofdopaminergicmodulatorsoncognition

11:00 PhilipMcGuire(InstofPsychiatry,London) S16 Neuroimagingofdopaminefunctioninthehumanbrain

SYMPOSIUM 5 – Queen’s Suite 1 ComputationalPsychopharmacology Chairs:JonathanRoiser(UniversityCollegeLondon);QuentinHuys(UnivofZürich)

09:00 QuentinHuys(UnivofZürich) S17 Anintroductiontocomputationalmodellingforpsychopharmacologists

09:30 TiagoMaia(UnivofLisbon) S18 Catecholaminergicdisturbancesandattention-deficit/hyperactivitydisorder


10:30 TimBehrens(UnivofOxford) S19 Imagingcompetitionmechanismsinlivinghumans

11:00 DouglasSteele(UnivofDundee) S20 Abnormalvaluationindepression,schizophreniaandaddiction

arrogate

25 25

H 2013

Tuesday

SYMPOSIUM 6 – Queen’s Suite 2 Alzheimer’sdiseaseearlydetectionandearlyeffectivetreatment Chair:BarbaraSahakian(UnivofCambridge)

09:00 JohnHardy(UniversityCollegeLondon) S21 Geneticanalysispointstomicroglialactivationasakeyeventinthe pathogenesisofAlzheimer’sdisease

09:30 WimRiedel(CambridgeCognition) S22 Enablingearlydetectionandinterventionindementia


10:30 JohnO’Brien(UnivofCambridge) S23 Neuroimagingasabiomarkerfordifferentformsofdementia

11:00 JeffreyNye(JanssenPharmaceuticals) S24 DiseasemodifyingdrugsforAlzheimer’sdisease:perspectivesfroma drugdeveloper’spointofview

11:45-12:45 BAP Post-doc Symposium – Queen’s Suite 1 Translationalautismresearchfordrugdiscovery Chair:StephanieMcTighe(Pfizer,Massachusetts)

11:45 StephanieMcTighe(Massachusetts) PD1 ImpairedlearningandattentionintheBTBRmousemodelofautism

12:00 MichaelSchmeisser(UlmUniv) PD2 TranslationalaspectsinShankmutantmice

12:15 JamieHorder(InstofPsychiatry,London) PD3 Multimodalneuroimaginginthesearchforautismtreatmenttargets

12:30 HilgoBruining(RudolfMagnusInst,Utrecht) PD4 DisruptionofaprotocadheringeneidentifiedbyQTLmappingofsocial memoryinmice,offersamodeltostudypervasivedefectsinbehavior andcorticaldevelopment

12:45 Editorial Board Meetings – Meeting Room 1 ForJournalofPsychopharmacologyandTherapeuticAdvancesin Psychopharmacology

13:00-15:00 PosterSession2inHallH

AffectiveDisorders2/Neuropharmacology/PsychomotorStimulants/Substances ofAbuse/Schizophrenia

26


26 Tuesday

TUESDAY GROUP A: AFFECTIVE DISORDERS 2

Acutetreatmentwith13-Cis-retinoicacidinducesadose-dependentnegativecognitiveaffective TA01 biasinratsClarke B,StuartSA,RobinsonESJ

Centralamygdalalesionsblockantidepressant-inducedpositiveaffectivebiasinrats TA02Stuart SA,ButlerP,NuttDJ,RobinsonESJ

ElevatedVMAT1expressionassociatedwithtransientpost-natalfluoxetineexposureinWistar TA03 ratscorrelateswithbehaviouraldespairRegan CM,HediganK,MurphyKJ

EffectsofReboxetineonemotionalprocessinginhealthyvolunteersmaybedeterminedby TA04 COMTval158metgenotypeMowlem FD,BautistaCE,GibbsAA

Adverseeffectsfromantidepressanttreatment:FindingsfromtheGENPODstudy TA05Crawford A,LewisS,NuttD,PetersTJ,CowenP,O’DonovanMC,WilesN,LewisG

Nextgenerationsequencing:Beyondgeneticassociation TA06Fox JC,CarrTH,KeelerS,McLoughlinMJ,McCarthyDJ,NgM,RunswickS

Anti-anhedoniceffectsofketamineanditsneuralcorrelatesindepression TA07Lally N,NugentAC,LuckenbaughDA,RoiserJP,ZarateCAJrThis will also be presented orally at 15:15 on Tuesday

Efficacyandtolerabilityoftranscranialdirectcurrentstimulationinmajordepression: TA08 asystematicreviewMeron D,GarnerMJ,BaldwinDS

DiagnosticStatuspredictionsusingstructuralandfunctionalMRIinmajordepression TA09Johnston BA,GradinVB,MwangiB,StirlingM,WalkerK,MacFarlaneJ,MatthewsK,SteeleD

Investigatingdimensionsofrewardastraitmarkersfordepression TA10McCabe C

Aberrantrewardlearninginpatientswithfunctionalmovementdisordersandunmedicated TA11 majordepressionNord CL,WinstonJS,PareesI,HuysQJM,RoiserJP,EdwardsMJ,DolanRJ

Electrophysiologicalcorrelatesofself-blamingbiasinremittedmajordepressivedisorder TA12Gethin JA,El-DeredyW,LytheK,ZahnR

Screeningforphysicalhealthproblemsinmooddisorderserviceoutpatients TA13Lack DA,HoltRIG,BaldwinDS

arrogate

27 27

H 2013

Tuesday

Subjectivesymptomseverityandlong-termoutcomeoftreatment-resistantdepression TA14Schoeler T,RaneLJ,FekaduA,WoodersonS,PoonL,MarkopoulouK,StrawbridgeB, CleareAJ

Longtermoutcomeinpatientstreatedinaspecialistinpatientunitfortreatmentresistant TA15 depressionWooderson SC,FekaduA,MarkopoulouK,RaneLJ,PoonL,JuruenaMF,CleareAJ

Depressioninpregnancy:adverseobstetricandfoetaloutcomes TA16Sundaresh S,ConroyS,OsborneS,PawlbyS,MarshMS,ParianteCM

Doyourneighboursmatter?Ethnicdensityinwomenwithpostnataldepressionandwith TA17 personalitydisorderinLondon,UKDu Preez A,ConroyS,ParianteCM

Real-timefMRIneurofeedbackcanimproveamygdalaregulationduringemotionalstimulation TA18Brühl AB,ScherpietS,SulzerJ,StampfliP,SeifritzE,HerwigU

TUESDAY GROUP B: NEUROPHARMACOLOGY

Evidenceforlithium-likeeffectsofebselenon5-HT2Areceptorfunctionmediatedvia TB01 IMPaseinhibitionAntoniadou I,ArsiwalaT,BuchmuellerD,KouskouM,SinghN,VasudevanS,ChurchillG, SharpT

THCelicitsveryhigh-frequencygammaoscillations TB02Morrison PD,NottageJ,EnglundA,ffytcheD

DopamineD3receptorblockadeviageneticdeletionorthenovelatypicalantipsychotic TB03 S33138increasesadultneurogenesisEgeland MT,SvenningssonP,MillanMJ

Neurotoxin-inducedlossofcholinergicfunctioninthedorsalstriatumofwildtypemice TB04 causeslocomotorhyperactivityinthelight/darkexplorationboxGrimmé AJ,NutterK,HuntSP,StanfordSC

P-glycoproteinandCNSantihistamineeffectsinhealthyvolunteers TB05Conen S,TheunissenEL,VermeerenA,MehtaM,RamaekersJG

BuprenorphineaugmentationinthetreatmentofrefractoryOCD TB06Aziz VM,LiddellMB,BriggsP,KanakkehewaN,RawiO,RobertsE

Effectoflisdexamfetamineinaratmodelofbinge-eatingdisorder TB07Heal DJ,VickersSP,HackettD,HutsonPH

28


28 Tuesday

Pharmacokineticandpharmacodynamicprofilesoftheprodrugstimulantlisdexamfetamine TB08 dimesylateinchildrenandadolescentswithADHDCoghill D,SorooshianS,ErmerJ,AdeyiB,SquiresL,CivilR

Posthocresponderanalysescomparingtheefficacyoflisdexamfetaminedimesylateand TB09 osmotic-releaseoralsystemmethylphenidateinchildrenandadolescentswithattention-deficit/hyperactivitydisorderCoghill D,BanaschewskiT,LecendreuxM,SoutulloC,JohnsonM,ZuddasA,AdeyiB, AndersonC,HigginsN,SquiresL,CivilR

TUESDAY GROUP C: PSYCHOMOTOR STIMULANTS

Theneurodevelopmentalandbehaviouraleffectsofmethamphetamineexposureduring TC01 pregnancyinratsMcDonnell Dowling K,MacEoinV,WalshS,O’BrienS,KellyJP

Theeffectsofdifferentroutesofadministrationofmethylphenidateonattentionand TC02 impulsecontrolinanovel5CSRTTWood CM,AbdelkadarS,PalmerZ,RobinsonESJ

LowperformingratsmodeltheinattentivesubtypeofadultADHDinthe5-choice TC03 continuousperformancetask(5C-CPT)Tomlinson A,NeillJC,MarshallKM

ReactivationofMecp2reversesbehaviouralabnormalitiesinafemalemousemodelof TC04 RettSyndromeRiedel G,RobinsonL

Genotype-dependentnoradrenergiceffectsonmemory:aproof-of-conceptstudy TC05Wade M,KnightJ,GibbsA

Methylphenidateinducedpsychosis:Asystematicreviewofcurrentliterature TC06Chikodzore MLD,BrinkL

TUESDAY GROUP D: SUBSTANCES OF ABUSE

Avoidanceofhealthwarninginformationamongcigarettesmokers TD01Maynard OM,AttwoodA,O’BrienL,BrooksS,HedgeC,LeonardsU,MunafoMR

Abehaviouralmeasureofsensation-seekinginhumans TD02Norbury A,Kurth-NelsonZ,DayanP,RoiserJP,HusainM

arrogate

29 29

H 2013

Tuesday

Pramipexoledecreasesurgestosmokeandredressesanimbalancebetweendrugand TD03 non-drugrewardFreeman TP,DasRK,KambojSK,CurranHVThis will also be presented orally at 15:00 on Tuesday

Effectsofacuteanxiogenucchallengeongoal-directedcontrolofhumandrugseekingbehaviour TD04Davidson AH

Cannabidiolreducescigaretteconsumptionintobaccosmokers:Preliminaryevidence TD05Das RK,MorganCJA,JoyeA,CurranHV,Kamboj,SK

Theacuteandchroniceffectsofcannabinoidsonemotionalprocessing TD06Hindocha C,FreemanTP,SchaferG,GardenerC,DasRK,WollenbergO,CarterV, MorganCJA,Curran,HV

Recreationaldrugsandsexualexperiences:across-sectionalinternetsurvey TD07Lawn WM,WinstockAR

Distinguishingtrustworthyanduntrustworthyfacesinmethadone/buprenorphinemaintained TD08 opiateusersMokrysz CA,WellingtonC,CharlesM,O’RyanD,CurranHV

InternalandTest-RetestReliabilityoftheModifiedStroopandtheDisengagementTask TD09Ataya A,AdamsS,AttwoodAS,MunafoM

Restingstatesynchronyinanxiety-relatedcircuitsofabstinentalcoholdependentpatients TD10Orban C,McGonigleJ,ErritzoeD,KalkNJ,RabinerEA,NuttDJ,Lingford-HughesAR

Lapsesofattentionduringdrivinginthealcoholhangoverstate TD11Bervoets AC, de Klerk S,VremanRA,OlivierB,BrookhuisKA,RothT,VersterJC

SeverityofAlcoholdependenceandCraving:ComponentsoftheDesireforAlcohol TD12 QuestionnaireSinclair JMA,PascheSC,GarnerMJ,BaldwinDS

Computerassistedself-infusionofethanol(CASE):Apredictionofthefutureriskforaddiction? TD13Mick I,O’ConnorS,VitvitskiyV,WinieckiP,MannKF,ZimmermanUS

Ibibiergosum(IhavedrunkthereforeIam) TD14Christiansen P,JonesA,RigbyP,FieldM

Caffeinealtersthebehaviouralandthermoregulatoryresponsestomephedronewithout TD15 causinglong-termneurotoxicityShortall SE,ByattS,KaufmanN,LipmanH,SmithG,GreenAR,FoneKCF,KingMV

Mephedrone,CannabisandAlcohol:Thenewriskstomentalhealth TD16Cullen AB,ParrottA

30


30 Tuesday

StructuraldifferencesinthebrainassociatedwithheavyKetamineuse TD17Cole AJ,StoneJM,PepperFS,FurbyH,HowesO,MorganCJA

EstablishingPavloviantoinstrumentaltransferwithorallydeliverednicotineandfentanyl TD18 inrats:routetodevelopingmoreeffectivedrugcessationmedicationsFisher BF

Profilesoflisdexamfetamine,methylphenidateandmodafinilaspositivereinforcersinrats TD19 trainedtoselfadministercocaineHeal DJ,BuckleyNW,FranceCP,HackettD

TUESDAY GROUP E: SCHIZOPHRENIA

Anauditofantipsychoticprescriptionpracticeinapsychiatricservice TE01Achor M

Prevalenceofhigh-doseandcombinedantipsychoticprescribinginmentalhealthservices TE02 acrosstimeandclinicalsettingsBarnes TRE,AdroerR,PatonC

Evaluatingtheuseofintramuscularclonazepaminrapidtranquilisation TE03Bleakley S,EkelundA,HenryR

Antipsychoticsprescribingtrendsandpatternsamongchildrenandadolescentswithsevere TE04 mentalillnessinTaiwan-alongitudinalpopulation-basedstudyChang HC,McCroneP,SuKP

Clozapineaugmentationinalowsecureforensicservice TE05Deslandes PN,SewellRDE

PractitionerattitudestoClozapineinitiation TE06Gee SH,TaylorDM

Effectsofantipsychoticsonbonemineraldensityandprolactinlevelsinpatientswith TE07 schizophrenia:a12monthsprospectivestudyinChinaHou R,WangM,JianJ,MiG,QiuH,CaoB,TangM

IsthequalityofreportingforantipsychoticPhaseII/IIItrialsgoodenough? TE08Patel MX,CollinsS,HellierJ,BhatiaG

PaliperidonePalmitateforrecurrentoculogyriccrisisinapatientwithschizophrenia TE09Ramasamy K,BhandariN

MTHFR677C/Tgenotypeisassociatedwithantipsychoticdrug-inducedweightgainin TE10 patientswithschizophreniaSrisawat U,DaltonCF,ReynoldsGP

arrogate

31 31

H 2013

Tuesday

DNAmethylationofthe5-HT1Areceptorgenepromoterisassociatedwithnegative TE11 syndromeresponsetoantipsychoticdrugtreatmentTang H,SrisawatU,DaltonCF,ZhangZJ,ReynoldsGP

CohortstudyofpaliperidonepalmitatelongactinginjectiontreatmentinSussex TE12Whale R,FialhoR

SeverecognitiveimpairmentwithinamultiplyaffectedSouthAsianfamilywithahighrisk TE13 ofschizophreniaBeetschen ER,TomlinsonA,HarteM,MahmoodT,NeillJC

Alteredhippocampalandstriatalfunctionduringsalienceprocessinginpeopleatultra TE14 highriskforpsychosisBossong MG,AllenP,HowesOD,SamsonC,QuinnB,BonoldiI,McGuireP

Compromisedmyelinintegrityandperipheralinflammatorymarkersinfirstepisodepsychosis TE15Giordano A,DeoniS,McMullen,FaridA,SimmonsA,MorganC,ReisMarquesT, MondelliV,ParianteC,TurkheimerF,WilliamsS,DazzanP

Effectofinflammationonmentalandphysicalclinicaloutcomesinfirstepisode-psychosis TE16Russell AE,CiufoliniS,DiFortiM,GiordanoA,MarquesTR,TaylorH,MorganC, MurrayRM,DazzanP,ParianteCM,MondelliV

Relationshipbetweenthalamicglutamatelevelsandclinicaloutcomeinindividualsatultra TE17 highriskforpsychosisEgerton A,StoneJ,ChaddockC,McGuireP

Canweusecortisollevelstopredictclinicaloutcomeinpatientswithfirst-episodepsychosis? TE18Mondelli V,CiufoliniS,HandleyR,MarquesTR,TaylorH,ZunszainP,DiFortiM,MurrayRM, DazzanP,ParianteCM

Alteredneurochemicalprofileintheratprefrontalcortexfollowingmaternalimmuneactivation: TE19 alongitudinalinvivo1HmagneticresonancespectroscopystudyVernon AC,LythgoeDJ,WilliamsSCR,SoPW,KapurSThis will also be presented orally at 15:15 on Tuesday

Assessmentofworkingmemoryandsocialbehavioursinmicewithgeneticmodificationofthe TE20 schizophrenia-riskgeneMAP2K7Wilson C,ThomsonDM,MorrisB,PrattJA

Ratsrearedinisolationfromweaningshowincreasedexpressionofglutamatetransportersand TE21 glutamateuptakeintheprefrontalcortexandhippocampusFachim HA,BosaipoNB,MoriyamaKK,SantosMR,IyomasaMM,BeleboniRO,RosaMLNM

Disc1mutationinducedalterationsincerebralmetabolismandintheresponsetoacute TE22 ketaminetreatment:acomparisonofthreedifferentDisc1mutationsDawson N,WinchesterCL,McVieA,ThomsonDM,DunlopJ,BrandonNJ,MorrisBJ,PrattJAThis will also be presented orally at 15:00 on Tuesday

32


32 Tuesday

Evaluationofsub-chronicketaminetreatmentinarodentmodeloftheIowaGamblingTask TE23Jermy B,RixR,ShoaibM

Chronicadministrationofhaloperidolinnaiverats;consequencesforcerebralmorphology TE24 andinflammationBloomfield PS,HowesOD,dePaolaV

PreliminaryfindingsofanovelelectrophysiologicalassayforNMDAreceptorautoantibodies TE25 inpsychosisAdams T,WatsonS,WilsonS,CarrollB,MelodyJ,GargH,MacMillanI,BrydonT,HallS,CunninghamMThis will also be presented orally at 15:30 on Tuesday

15:00-16:00 SHORT ORAL PRESENTATIONS – Hall D, Queen’s Suite 1 and Queen’s Suite 2

SHORT ORALS 1 – Hall D SpecialK:NewHorizons Chair:DavidNutt

15:00 DISC1mutationinducedalternationsincerebralmetabolismandinthe TE22 responsetoacuteketaminetreatment:Acomparisonofthreedifferent DISC1mutations NeilDawson (WinchesterCL,McVieA,ThomsonDM,DunlopJ,BrandonNJ,MorrisBJ, PrattJA)

15:15 Anti-anhedoniceffectsofketamineanditsneuralcorrelatesindepression TA07 NiallLally (NugentAC,LuckenbaughDA,RoiserJP,ZarateCAJr)

15:30 Theeffectofketamineonfunctionalconnectivityanditsmodulationby MC13 risperidoneandlamotrigine RichardJoules (DoyleOM,O’DalyO,DeSimoniS,MehtaMA)

15:45 Psychosis-likeeffectsofketamine–relationshiptobrainactivity ME01 MitulMehta (StoneJ,DietrichC,ReedL,DeSimoniS,KrystalJ,BarkerGJ)

arrogate

33 33

H 2013

Tuesday

SHORT ORALS 2 – Queen’s Suite 1 WindowsontheBrain Chair:KevinFone

15:00 OptogeneticstimulationofglutamatergicneuronesintherodentprefrontalMC19 corteximprovesdiscriminationperformanceinanobjectrecognitiontask AbigailBenn (StuartSA,BarkerGRI,TeschemacherA,WarburtonEC,RobinsonESJ)

15:15 Alteredneurochemicalprofileintheprefrontalcortexfollowingmaternal TE19 immuneactivation:Alongitudinalinvivo1Hmagneticresonance spectroscopystudy AnthonyVernon (LythgoeDJ,WilliamsSCR,SoPW,KapurS)

15:30 PreliminaryfindingsofanovelelectrophysiologicalassayforNMDA TE25 receptorautoantibodiesinpsychosis TomAdams (WatsonS,WilsonS,CarrollB,MelodyJ,GargH,MacMillanI,BrydonT, HallS,CunninghamM)

15:45 Theeffectofprefrontaltranscranialdirectcurrentstimulationonattention ME08 networkfunctioninhealthyhumans JoannaMiler (MeronD,BaldwinDS,GarnerM)

SHORT ORALS 3 – Queen’s Suite 2 RewardandChoice Chair:ValCurran

15:00 Pramipexoledecreasesurgestosmokeandredressesanimbalance TD03 betweendrugandnon-drugreward TomFreeman (DasRK,KambojSK,CurranHV)

15:15 Investigatingrewardfunctionasabiomarkerandtargetfor MG08 pharmacologicaltreatments TA10 CiaraMcCabe

15:30 Effectsofrewardexpectancyonattentionalbiasforrewardingstimuli MC04 areoutcome-specific PawelJedras (JonesA,FieldM)

15:45 TheeffectofMDMAadministrationonthepruningofdecisiontrees MC14 PaulFaulkner (HuysQ,CurranHV,NuttD,Carhard-HarrisR,ErritzoeD,DayanP, RoiserJ)

34


34 Tuesday

16:00 BAP Psychopharmacology Award Winners – oral presentations – Queen’s Suite 1 ChairedbyPaulHarrison

16:00 AngelaAttwood(UniversityofBristol) PW2 D-cycloserinedoesnotimprovedrug-relatedcueexposure:whatcanwe learnfromanimaldata?

16:20 JonathanRoiser(UniversityCollegeLondon) PW3 Individualdifferencesinpsychopharmacology:Wheredotheycomefrom andwhyshouldwecare?

16:40 Kuan-PinSu(ChinaMedicalUniversity) PW4 Omega-3fattyacidsindepression:Thebiological,therapeuticand preventiveimplications

19:30 Reception and Conference Dinner at The Royal Hall, Harrogate

arrogate

35 35

H 2013

Conference DinnerSmoked Salmon and Asparagus Tartlet

with Chicory Leaves and Wharfe Valley Lemon Oil

Vine Tomato, Buffalo Mozzarella and Sun Blush Tomato Stack with Pesto Dressing, Aged Balsamic and Olive Oil

(For those who have ordered a vegetarian meal)

-o0o-

Rack of Lamb with a Redcurrant and Rosemary Jus

Roasted Pumpkin and Vegetable Brochette, Chargrilled Spears of Asparagus, Wild Rice and Spiced Tomato Dressing

(For those who have ordered a vegetarian meal)

-o0o-

Yorkshire Clotted Cream with Strawberry Millefeuille and Strawberry Coulis

Dinner will be followed by the presentation of the 2013 BAP Awards

Tuesday

36


36

WEDNESDAY31JULY09:00 BAPDeskopensintheFoyeroftheQueen’sSuite

09:30 Symposia 7, 8 and 9 in Hall D, Queen’s Suite 1 and Queen’s Suite 2

SYMPOSIUM 7 – Hall D Canpsychologicalconstructsmakegooddrugtargets?Theexampleofsalience dysregulationinschizophrenia Chairs:PaulaMoran(UnivofNottingham),ColmO’Tuathaigh (UniversityCollegeCork)

09:30 PaulaMoran(UnivofNottingham) S25 Assessingantipsychoticdrugeffectsonsalienceinanimalmodels

10:00 ColmO’Tuathaigh(UniversityCollegeCork) S26 Salienceasabehaviouralphenotypeingeneticandpharmacologicalanimal modelsofschizophrenia


11:00 AntonLoonen(UnivofGroningen) S27 Clinicalstudiesofsaliencedysregulationandimplicationsfornosologyof schizophrenia

11:30 PeterLiddle(UnivofNottingham) S28 Thesaliencenetworkinschizophreniaanditspotentialasanewtreatment targetforschizophrenia

SYMPOSIUM 8 – Queen’s Suite 1 Novelinnovationinmonitoringsymptomsandtreatmentsforschizophreniaand bipolardisorder Chair:BarbaraSahakian(UnivofCambridge)

09:30 TorgnySvensson(KarolinskaInst) S29 Novelandimprovedpharmacologicaltreatmentinschizophrenia

10:00 GaryGilmour(Lilly,Windlesham) S30 NovelmGlu5positiveallostericmodulator 10:30 RefreshmentsinHallH

11:00 ClareKillikelly(UnivofCambridge) S31 Cognitivetraininginschizophrenia

Wednesday

arrogate

37 37

H 2013

Wednesday

11:30 GuyGoodwin(UnivofOxford) S32 Monitoringsymptomsinbipolarpatients:TrueColours

SYMPOSIUM 9 – Queen’s Suite 2 Theimpactofinflammatorychallengesonmentalfunction Chairs:CarminePariante(InstofPsychiatry,London),BrianLeonard (NationalUnivofIreland,Galway)

09:30 MatthewTaylor(InstofPsychiatry,London) S33 Effectofinterferon-alphatreatmentoncorticalglutamatergicfunction

10:00 AyeMuMyint(LudwigMaximilianUniv,Munich) S34 Inflammationandthegenerationofneurotoxins:cantheactivationofthe tryptophan-kynureninepathwayindepressionandschizophreniasuggest noveltargetsforpsychotropicdrugdevelopment?


11:00 NeilHarrison(UnivofSussex) S35 Inflammatoryeffectsonmedialtemporallobemetabolismimpairhuman spatialmemory

11:30 JohnCryan(UniversityCollegeCork) S36 Thegut-brainaxisandinflammationinmajorpsychiatricdisorders: Couldthisbeanewapproachtomodulatingabnormalbrainfunction?

12:00 Endofthe2013SummerMeeting

38


38

Comeandjointhecelebrationsforthe40thanniversaryoftheBAP

Sunday20–Wednesday23JulyRobinsonCollegeandWestRoadConcertHall,Cambridge

SocialoccasionsatTheFitzwilliamMuseumandGirtonCollege

ConfirmedSymposia:

Monday21July1. Predictorsofclinicalresponseindepression2. Tobaccoaddictioninschizophrenia:atranslationalinvestigation3. ADHDandobesity:Overlappingneurobiologyanddevelopmentof pharmacologicaltreatments

Tuesday22July4. Theadolescentbrain–Akeystageinthedevelopmentofpsychiatric disorders?5. ChickensandEggs:SeparatingCauseandEffectinDrugAddiction6. GeneticpathwaysinPsychosis:theroadtonewtreatments?

Wednesday23July7. Endocannabinoidsinpsychiatry:currentunderstandingandfuture treatments8. TheElectronicCigarette:fromBasicPharmacologytoSmokingHarm ReductionandCessation9. Dopamine,impulsecontroldisordersandParkinson’sdisease

DavidNuttwillpresentthe2014GuestLecture

PlenaryMentalHealthSession: Ispsychiatricdiagnosisrelevanttopsychopharmacologicaltreatment?

arrogate

39 39

H 2013

THEBRITISHASSOCIATIONFORPSYCHOPHARMACOLOGYTheBAPwasfoundedin1974,withthegeneralintentionofbringingtogetherthosefromclinicalandexperimentaldisciplinesaswellasmembersofthepharmaceuticalindustryinvolvedinthestudyofpsychopharmacology.TothisendtheAssociationarrangesscientificmeetings,fostersresearchandteaching,encouragespublicationofresultsofresearchandprovidesguidanceandinformationtothepubliconmattersrelevanttopsychopharmacology,whereappropriate.

TheBAPhasanextensiveeducationalportfolio.TheCertificateinClinicalPsychopharmacologyprovidesup-to-dateCPDandconsistsofsixmodulesheldeachyear–AnxietyDisorders,Schizophrenia,AffectiveDisorders,SubstanceMisuse,OldAgePsychiatry,ChildandAdolescentPsychopharmacology.

TwiceyearlytheBAPholdsthree-dayMasterclassesincentralLondon.TheseimmenselypopularcoursesupdatepracticinghealthcareprofessionalsoncurrentissuesinpsychopharmacologyandaretaughtbyleadingUKpsychopharmacologists.

Since2011theBAPhasofferedanOnlineCPDResource,aregularly-updatedresourcepresentedbyacknowledgedexpertsandopinionleadersintheirrespectivefields.

TheBAPlaunchedthePre-clinicalCertificateinPsychopharmacologyinJuly2001,toincreaseawarenessof,andexpertisein,pre-clinicalpsychopharmacologythroughtheprovisionofaseriesoftrainingmodulesthatcoveredkeyaspectsofresearchonanimalsandhumansaswellascareerdevelopment.Themodularcoursehasevolvedovertheyearsandwillbere-launchedinFebruary2014asa4-dayresidentialcourseinCambridge.

MembershipofBAPisopentoanyqualifiedworkerinadisciplinerelevanttopsychopharmacology.Existingmembersincludepharmacologists,psychiatrists,psychologists,neurobiologistsandpharmacists.

Full Membership:ApplicantsareeligibleforFullMembershipiftheycandemonstrateinvolvementinareasrelevanttopsychopharmacologyby,forexample,qualifications,publicationsorresearchactivity.

Training Membership:Thiscategoryisdesignedtosupportscientistsearlyintheircareerwhohavealimitedincomesuchasaresearchstudentship.Forthisreasontrainingmembershipisnotavailabletomedicalapplicants(i.e.doctors)otherthaninexceptionalcaseswhenitmaybeawardedatthediscretionoftheHonoraryGeneralSecretary.InadditiontrainingmembershipwillonlybeawardedtothoseregisteredforaUniversityresearchdegreee.g.MSc,PhD.BAPsupportstrainingmembersattendingthesummermeetingsbyofferingareducedregistrationrateandtheoptiontoapplyforabursaryifpresentingdata(seemoredetailedcriteriaonwebsite).Trainingmembershipislimitedtoa5-yearmaximumperiod(fromthepointofregistrationasatraineemember)oruntilthetraineeattainsapermanentposition(e.g.inacademiaoracompany).

Benefits of BAP membership include:• FREEsubscriptionandonlineaccesstotheJournalofPsychopharmacology*• ReducedregistrationfeesfortheannualSummerMeeting• HalfpricesubscriptiontotheOnlineCPDResource• Eligibilityforprizesandawards• StudentbursariesfortheBAPSummerMeeting• Reducedregistrationfeesforselectedpartnerassociationevents• BAPNewsletter• VotingforBAPOfficersandCouncil*• Beingpartofoneofthelargestnationalpsychopharmacologyassociationsintheworld

*Fullmembersonly

Applyformembershipnowatthewebsitehttp://bap.org.uk/membership

40


40

APPLICATIONFORMEMBERSHIPOFTHEBAPThisapplicationmustincludeeitherthenameofaFullMemberofBAPwillingtosupporttheapplicant,

oracopyoftheapplicant’scurriculumvitae

APPLICATION FOR MEMBERSHIP OF THE BAP

This application must include either the name of a Full Member of BAP willing to support the applicant, or a copy of the applicant’s curriculum vitae

TITLE ................... FIRST NAME ............................. LAST NAME..................................... DATE OF BIRTH .......................................................... APPLYING FOR: FULL MEMBERSHIP @ £80 p.a. TRAINING MEMBERSHIP* @ £20 p.a. *This requires a supporting statement from your BAP sponsor CURRENT WORK ADDRESS: ................................................................................................. ............................................................................................................................................ TEL: .................................................................... FAX:......................................................... EMAIL: ................................................................................................................................ Year of PhD award (if applicable) ......................................... DEGREES (including dates and awarding body) ........................................................................................................................................... PRESENT POST: ................................................................................................................... PLEASE TICK THAT WHICH BEST DESCRIBES YOUR STATUS/INTEREST: Clinical Pre-clinical Industrial Other ARE YOU RESEARCH ACTIVE? Yes No SPECIFIC INTEREST IN PSYCHOPHARMACOLOGY (i.e. psychiatric, psychological, experimental, pharmaceutical) .......................................................................................................................................... NAME OF BAP FULL MEMBER WILLING TO SPONSOR THIS APPLICATION: .......................................................................................................................................... SIGNATURE OF APPLICANT: ..................................................... DATE: .............................. *SUPPORTING STATEMENT FOR SPONSORS OF TRAINING MEMBERSHIP APPLICANTS I certify that the person named above qualifies for BAP Training Membership on the grounds of (a) being a full or part-time student with a limited income OR (b) other reason (please specify) SIGNATURE OF SPONSOR: ………………………………………. NAME (print): ………………………………..

Please send completed Application Form to the BAP Office 36 Cambridge Place, Hills Road, Cambridge CB2 1NS Tel: 44 (0) 1223 358 395 Fax: 44 (0) 1223 321 268

Email: [email protected] (Lynne Harmer, Assistant to the Executive Officer)

DO NOT SEND PAYMENT WITH THIS FORM

arrogate

41 41

H 2013

2014 Pre-Clinical Certificate Residential Course

Royal Cambridge Hotel Trumpington Street Cambridge CB2 1PY

Sunday 23 to Wednesday 26 February 2014 In 2001 the BAP launched the Certificate in Pre-Clinical Psychopharmacology with the support of the BBSRC. The existing modular Certificate programme has been highly successful. The Certificate will now move to a new format and will become a 4 day residential course.

The aim of this programme is to increase awareness of, and interest in, experimental psychopharmacology through the provision of a cluster of training modules which will cover key aspects of research on animals and humans (as well as professional development in this field). The modules will have particular relevance to Home Office Licence holders as they will provide essential continuing professional development for researchers in industrial and academic centres whose work involves experiments on animals.

This course will benefit novice and experienced psychopharmacologists, as well as those working in related fields, by encouraging appraisal and refinement of experimental design, in addition to providing training in essential skills.

The following topics will be covered • Principles of Psychiatry • Pharmacokinetics in Psychiatry • The Molecular Biology of the Mind • Statistics and Experimental Design • Scientific Validity in Preclinical Psychopharmacology • Preclinical Models and Behavioural Psychopharmacology • Combining Neurobiology and Behaviour • Neuroimaging in Psychopharmacology

In addition to taught sections, the residential course will include round-table debates, practical sessions and a team project, and a full social programme.

Highlights Guest lectures will be given by Professor Barbara Sahakian (Cambridge), Professor David Nutt (London) and Professor Trevor Robbins (Cambridge) To complete a registration of interest form, please go to www.bap.org.uk/educationevent.php?trainingTypeID=1 Course Directors Dr Paula Moran and Professor Hugh Marston

42


42

arrogate

43 43

H 2013

Documents

20093 BAP Programme 2013 · 2013 Prizes and Awards 8 Acknowledgements 9 Programme in Detail Sunday 28th July 10 ... Guest Lecture: Helen Mayberg, Hall D on Monday at 11:45 Internet